MIT News breed · Science

Automated LNP Production Speeds RNA Therapy Development

MIT researchers have developed an automated system to produce lipid nanoparticles (LNPs) for RNA therapies faster and with greater control over size and shape, potentially accelerating drug development.

Current LNP production methods are often slow and lack precise control over particle characteristics, which are vital for targeting specific tissues.

The new automated process refines a two-step mixing technique. Adjusting the delay between mixing steps controls particle size, while buffer concentration alters shape.

This system integrates real-time particle size measurement and can be programmed to achieve target sizes, automatically adjusting parameters if needed.

The automation allows for rapid testing of how input variations affect LNP size and shape, feeding data into a machine-learning model for prediction.

Precise size control is crucial as it dictates where LNPs accumulate in the body, making this method valuable for tailoring therapies.

The technology is patented and being commercialized as BIZON Labs, with support from MIT programs and funding from the FDA and National Cancer Institute.

AI-samenvatting op basis van de bron.